Quantum Cyber N.V. Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction
Quantum Cyber N.V. (QUCY) reported Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction of $16.26 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseRecognisedDuringPeriodForBadAndDoubtfulDebtsForRelatedPartyTransaction · last filed 2025-03-31
- Quantum Cyber N.V. expense recognised during period for bad and doubtful debts for related party transaction for the quarter ending 2023-12-31 was -$42.05K.
- Quantum Cyber N.V. expense recognised during period for bad and doubtful debts for related party transaction for the quarter ending 2023-09-30 was $42.05K.
- Quantum Cyber N.V. expense recognised during period for bad and doubtful debts for related party transaction for the quarter ending 2023-06-30 was $0.00.
- Quantum Cyber N.V. expense recognised during period for bad and doubtful debts for related party transaction for the quarter ending 2023-03-31 was $53.30K.
| Period end | Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction 3 month | Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction 6 month | Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction 6 month as first filed | Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction 9 month | Expense Recognised During Period For Bad And Doubtful Debts For Related Party Transaction 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $16.26K 20-F · filed 2025-03-31 | ||||
| 2023-12-31 | -$42.05K derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $53.30K 20-F · filed 2025-03-31 | |
| 2023-09-30 | $42.05K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16 | $42.05K derived: sum of 2 quarters · filed 2023-11-16 | $95.34K 6-K · filed 2023-11-16 | $95.34K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15 | $53.30K 6-K · filed 2023-08-15 | $53.30K derived: sum of 3 quarters · filed 2025-03-31 | $53.30K derived: sum of 4 quarters · filed 2025-03-31 | |
| 2023-03-31 | $53.30K 6-K · filed 2023-05-16 | $53.30K derived: sum of 2 quarters · filed 2025-03-31 | $53.30K derived: sum of 3 quarters · filed 2025-03-31 | ||
| 2022-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 20-F · filed 2025-03-31 | ||
| 2022-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2023-11-16 | $0.00 6-K · filed 2023-11-16 | |||
| 2022-06-30 | $0.00 6-K · filed 2023-08-15 | $470.00 6-K · filed 2022-09-07 | |||
| 2021-06-30 | $0.00 6-K · filed 2022-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |